T3D Therapeutics Begins Enrollment in the PIONEER Phase 2 Clinical Trial of T3D-959 in Patients with Mild to Moderate Alzheimer’s Disease

RESEARCH TRIANGLE PARK, N.C., Feb. 11, 2020 – T3D Therapeutics, Inc. (“T3D” ), a clinical stage drug development company engaged in the development of T3D-959, a new orally administered treatment for Alzheimer’s disease (AD), announced today the initiation of screening and enrollment for the PIONEER Phase 2 clinical trial for its product candidate T3D-959. T3D-959 is being evaluated for the treatment of patients with mild to moderate Alzheimer’s disease. T3D-959 is a small molecule, orally delivered, brain-penetrating dual nuclear receptor agonist designed to improve glucose and lipid metabolism dysfunctions present in AD and other neurodegenerative disorders. Read the Full Press Release Here

The release as fetched from its publisher. t3dtherapeutics.com ↗